Germany-based medical device company Transcatheter Technologies GmbH is making a bold stride into the transcatheter aortic valve implantation space, announcing 1st-in-man implantation of a device it says it intends to be the “the world’s best repositionable heart valve.” The young company faces some stiff competition in the repositionable TAVI arena, with medtech giants Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) also vying to get their next-generation repositionable TAVI systems on the market. “A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted,” Transcatheter Technologies CEO Dr. Wolfgang Goetz said in prepared remarks.
Help employers find you! Check out all the jobs and post your resume.
